Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reportsopen access
- Authors
- Yeom, Kyeong-Min; Song, Young-Gi; Yoo, Jeong-Ju; Kim, Sang Gyune; Kim, Young Seok
- Issue Date
- Jan-2024
- Publisher
- MDPI
- Keywords
- hepatocellular carcinoma; upper gastrointestinal bleeding; variceal bleeding; adverse event; bevacizumab
- Citation
- MEDICINA-LITHUANIA, v.60, no.1
- Journal Title
- MEDICINA-LITHUANIA
- Volume
- 60
- Number
- 1
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25921
- DOI
- 10.3390/medicina60010157
- ISSN
- 1010-660X
1648-9144
- Abstract
- Background and Objectives: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab/bevacizumab in patients with advanced hepatocellular carcinoma (HCC). Materials and Methods: We would like to introduce the cases of two patients who underwent bevacizumab reduction or discontinuation when VB occurred after atezolizumab/bevacizumab. Results: VB occurred in two patients who showed good tumor response after atezolizumab/bevacizumab treatment, and all VBs were successfully treated with endoscopic variceal ligations. In the first patient, VB did not occur as the tumor response decreased after a 50% reduction in bevacizumab. In the second patient, VB occurred again after a 50% bevacizumab reduction, so bevacizumab was discontinued and treatment with atezolizumab alone has been successfully maintained. Conclusions: Accordingly, we would like to suggest that considering bevacizumab dose reduction instead of changing to tyrosine kinase inhibitor may be a good clinical choice in atezolizumab/bevacizumab patients who develop VB.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25921)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.